Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 4/20 | 0.46 |
| ▸ | GSK3B | P49841 | 4/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | GSK3A | P49840 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | CHUK | O15111 | 2/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 2/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.46 |
| ▸ | PRKCG | P05129 | 2/20 | 0.46 |
| ▸ | CDK1 | P06493 | 2/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 2/20 | 0.46 |
| ▸ | CDK2 | P24941 | 2/20 | 0.46 |
| ▸ | MARK3 | P27448 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18080358 | 0.85 | CYP19A1 (0.48) | CYP19A1NPC1RAB9AKDRGSK3B | |
| SCHEMBL16631904 | 0.82 | RET (0.43) | CCNKCDK12 | |
| SCHEMBL16631387 | 0.79 | MPO (0.51) | CYP19A1NPC1RAB9AHRH4 | |
| SCHEMBL18081738 | 0.79 | CA1 (0.43) | KDRCDC7PTGS2FLT3 | |
| SCHEMBL16631733 | 0.78 | CYP19A1 (0.51) | CYP19A1NPC1RAB9AKDRGSK3B | |
| SCHEMBL19288896 | 0.78 | CYP19A1 (0.51) | CYP19A1NPC1RAB9AKDRGSK3B | |
| SCHEMBL16631902 | 0.77 | CYP19A1 (0.52) | CYP19A1NPC1RAB9AKDRGSK3B | |
| SCHEMBL16631905 | 0.76 | BRD4 (0.35) | GSK3BDYRK1A | |
| SCHEMBL16631731 | 0.74 | KCNMA1 (0.54) | CYP19A1NPC1RAB9AHRH4 | |
| SCHEMBL16631543 | 0.74 | ADORA3 (0.54) | RAB9AALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | CYP19A1 4868/4885NPC1 1636/4885RAB9A 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.